Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHBNKP)

• Drug Name: C-Met/PD-L1 CAR-T Cell Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHBNKP

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[3]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[4]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[6]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[7]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[8]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[9]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[10]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[7]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[11]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[12]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[13]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[14]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[15]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[16]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[18]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[19]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of Exelixis (2011).
• [4] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [11] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [14] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [16] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [17] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [18] National Cancer Institute Drug Dictionary (drug id 740856).
• [19] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [20] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.